claudiowall
Short

#Nasdaq #Biotech It ought to correct overbought

INDEX:NBI   Nasdaq Biotechnology Index
It ought to correct overbought Nasdaq Biotechnology Index:
The Nasdaq Biotech index             has grown about 50 percent since Yellen's valuation comments. Superarando por             mucho el desempeño de los indices composite y S&P500             , this boom is due primarily to the pharmaceutical companies who have monopolized the attention of investors the past few months, beyond the debate of whether exist a bubble formation the Nasdaq Biotechnology Index             It ought to correct their overbought at least 6% as it has done in later months

http://www.bloomberg.com/news/articles/2015-03-20/biotech-has-surged-massively-since-warning-from-the-fed
snapshot


Article:
Biotechs could be the early warning for stocks http://cnb.cx/1N9Sg68

The uncertainty caused by the excessive increase in the valuation of shares, based on the promises of extraordinary cash flows through products that are still in experimental stages of research and development is an increasingly risky. The appetite for higher-yielding assets and high risk is associated with the availability of liquidity injected by central banks in the market at low interest rates, when a change occurs in this scenario the liquidation of long positions will result in a significant correction that all expect.
Reply
English
English (UK)
English (IN)
Deutsch
Français
Español
Italiano
Polski
Türkçe
Русский
Português
Bahasa Indonesia
Bahasa Melayu
ภาษาไทย
Tiếng Việt
日本語
한국어
简体
台灣
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out